- Home
- TGTX vs PTCT Comparison
TGTX vs PTCT Comparison
Compare TGTX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- PTCT
- Stock Information
- Founded
- TGTX 1993
- PTCT 1998
- Country
- TGTX United States
- PTCT United States
- Employees
- TGTX N/A
- PTCT N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- TGTX Health Care
- PTCT Health Care
- Exchange
- TGTX Nasdaq
- PTCT Nasdaq
- Market Cap
- TGTX 5.5B
- PTCT 5.3B
- IPO Year
- TGTX 1995
- PTCT 2013
- Fundamental
- Price
- TGTX $32.18
- PTCT $71.58
- Analyst Decision
- TGTX Strong Buy
- PTCT Buy
- Analyst Count
- TGTX 5
- PTCT 17
- Target Price
- TGTX $48.20
- PTCT $73.24
- AVG Volume (30 Days)
- TGTX 1.8M
- PTCT 1.0M
- Earning Date
- TGTX 11-03-2025
- PTCT 11-04-2025
- Dividend Yield
- TGTX N/A
- PTCT N/A
- EPS Growth
- TGTX N/A
- PTCT N/A
- EPS
- TGTX 2.78
- PTCT 8.94
- Revenue
- TGTX $531,898,000.00
- PTCT $1,779,150,000.00
- Revenue This Year
- TGTX $82.31
- PTCT $119.02
- Revenue Next Year
- TGTX $49.05
- PTCT N/A
- P/E Ratio
- TGTX $11.61
- PTCT $8.03
- Revenue Growth
- TGTX 100.88
- PTCT 97.54
- 52 Week Low
- TGTX $25.28
- PTCT $35.95
- 52 Week High
- TGTX $46.48
- PTCT $73.98
- Technical
- Relative Strength Index (RSI)
- TGTX 39.20
- PTCT 71.08
- Support Level
- TGTX $31.07
- PTCT $66.10
- Resistance Level
- TGTX $34.74
- PTCT $73.98
- Average True Range (ATR)
- TGTX 1.70
- PTCT 2.58
- MACD
- TGTX -0.27
- PTCT 0.10
- Stochastic Oscillator
- TGTX 17.74
- PTCT 70.62
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.